Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ARTL 
Artelo Biosciences Inc (ARTL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ARTL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18
1 Year Target Price $18
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -70.72% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.39M USD | Price to earnings Ratio - | 1Y Target Price 18 |
Price to earnings Ratio - | 1Y Target Price 18 | ||
Volume (30-day avg) 2 | Beta 1.41 | 52 Weeks Range 3.94 - 28.60 | Updated Date 10/15/2025 |
52 Weeks Range 3.94 - 28.60 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -18.93 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -103.84% | Return on Equity (TTM) -356.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6309476 | Price to Sales(TTM) - |
Enterprise Value 6309476 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.22 | Shares Outstanding 1996703 | Shares Floating 1237026 |
Shares Outstanding 1996703 | Shares Floating 1237026 | ||
Percent Insiders 7.89 | Percent Institutions 1.06 |
Upturn AI SWOT
Artelo Biosciences Inc
Company Overview
History and Background
Artelo Biosciences Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics that modulate lipid signaling pathways, including the endocannabinoid system. Founded in 2011, it has focused on developing compounds to address diseases where lipid signaling plays a role.
Core Business Areas
- Oncology: Developing FABP5 inhibitors for cancer treatment, focusing on tumor growth and metastasis.
- Inflammation and Pain: Investigating compounds targeting the endocannabinoid system for pain and inflammatory conditions.
- Neurodegenerative Diseases: Exploring potential therapies for neurodegenerative diseases through lipid signaling modulation.
Leadership and Structure
Gregory D. Gorgas serves as Chief Executive Officer. The company has a board of directors and a management team overseeing research, development, and business operations.
Top Products and Market Share
Key Offerings
- ART27.13: A G-protein coupled receptor (GPCR) agonist designed to increase energy and appetite, being developed to treat cancer-related anorexia. Currently in Phase 1b/2a clinical trial. Competitors include dronabinol and megestrol acetate.
- FABP5 Inhibitors: Small molecule inhibitors targeting fatty acid binding protein 5 (FABP5) for solid tumors. Currently in preclinical development. Competitors include other cancer therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with significant investments in research and development. It is subject to regulatory scrutiny and long development timelines.
Positioning
Artelo Biosciences is a small-cap company focusing on niche areas within oncology and inflammation. Its competitive advantage lies in its unique approach to modulating lipid signaling pathways.
Total Addressable Market (TAM)
The TAM for cancer-related anorexia and solid tumor therapies is substantial, potentially reaching billions of dollars. Artelo is positioned to capture a share of this market with successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting lipid signaling
- Proprietary technology platform
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Early-stage development pipeline
- High risk of failure associated with drug development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new indications
- Positive clinical trial results
- Regulatory approvals and market access
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- GWPH
- MRK
- ABBV
Competitive Landscape
Artelo faces significant competition from established pharmaceutical companies with greater resources and more advanced pipelines. It differentiates itself through its novel approach to targeting lipid signaling pathways.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D progress and clinical milestones rather than revenue generation.
Future Projections: Future projections are highly speculative and dependent on successful clinical trials and regulatory approvals. Analyst estimates depend on clinical progress updates.
Recent Initiatives: Recent initiatives include advancing ART27.13 into Phase 1b/2a trials and continuing preclinical development of FABP5 inhibitors.
Summary
Artelo Biosciences is a development-stage company with a promising but risky pipeline targeting niche areas in oncology and inflammation. Its strength lies in its novel approach, but it needs to navigate the challenges of clinical development and regulatory approval. Success hinges on positive clinical trial results and securing partnerships or funding.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on independent research and consultation with a financial advisor. Market share data is approximate and based on available sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Artelo Biosciences Inc
Exchange NASDAQ | Headquaters Solana Beach, CA, United States | ||
IPO Launch date 2017-11-14 | President, CEO, Treasurer, Secretary & Director Mr. Gregory D. Gorgas M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.artelobio.com |
Full time employees 5 | Website https://www.artelobio.com | ||
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated/ weight loss with cancer; and ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, pain and inflammation, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.